Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Educating Recent Updates on Metastatic Non-small Cell Lung Cancer
share announcement

Educating Recent Updates on Metastatic Non-small Cell Lung Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 4249

Special Issue Editors

Dr. Biswarup Saha

E-Mail Website
Guest Editor
Department of Tumor Biology and GI Oncology, H. Lee Moffitt Cancer Center and Research Institute, 1209 USF Magnolia Drive, Tampa, FL 33612, USA
Interests: non-small cell lung cancer; lung adenocarcinoma; pancreatic ductal adenocarcinoma; tumor microenvironment; cancer metastasis; cancer epigenetics; post-translational modification of proteins
Dr. Hifzur R Siddique

E-Mail Website
Guest Editor
Molecular Cancer Genetics & Translational Research Lab, Section of Genetics, Department of Zoology, Aligarh, India
Interests: stem cells/cancer stem cells; non-coding RNAs; therapy resistance cancer; transgenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent updates on metastatic non-small cell lung cancer (NSCLC) delve into intricate aspects of lung adenocarcinomas and squamous cell carcinomas, investigating tumor microenvironment dynamics, epithelial to mesenchymal transition, and the role of desmoplasia towards lung cancer metastasis. Exploring tumor matrix biology, epigenetic modulation influencing tumor metastasis, and/or post-translational modifications of certain key tumorigenic factors adds depth to understanding the progression of cancer. Additionally, insights into the failure of immune surveillance mechanisms facilitating immune escape give a comprehensive understanding of the disease. Collectively, these recent findings in the field will enhance our grasp on the molecular intricacies driving metastatic NSCLC, paving the possible way for future advancements in the diagnosis of the disease and therapy.

Dr. Biswarup Saha
Dr. Hifzur R Siddique
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-small cell lung cancer
  • lung adenocarcinoma
  • lung squamous cell carcinoma
  • tumor microenvironment (TME)
  • epithelial to mesenchymal transition (EMT)
  • cancer metastasis
  • desmoplasia
  • tumor matrix biology
  • epigenetic modulations leading cancer metastasis
  • post-translational modifications (PTMs)
  • immune evasion

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 442 KiB  
Article
Lack of Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer in Real Life, with the Emergence of Immunotherapy
by Alice Daumas, Celestin Bigarre, Mohamed Boucekine, Audrey Zaccariotto, Bertrand Kaeppelin, Alice Mogenet, Etienne Gouton, Johan Pluvy, Pascale Tomasini, Xavier Muracciole, Sebastien Benzekry, Laurent Greillier and Laetitia Padovani
Cancers 2024, 16(23), 4122; https://doi.org/10.3390/cancers16234122 - 9 Dec 2024
Viewed by 972
Abstract
Background: Prophylactic cranial irradiation (PCI) is recommended to decrease the incidence of brain metastases (BM) in extensive-stage small-cell lung cancer (ESSCLC) without BM after response to chemotherapy. However, PCI is associated with significant neurocognitive effects, and new studies are debating its benefits. Moreover, [...] Read more.
Background: Prophylactic cranial irradiation (PCI) is recommended to decrease the incidence of brain metastases (BM) in extensive-stage small-cell lung cancer (ESSCLC) without BM after response to chemotherapy. However, PCI is associated with significant neurocognitive effects, and new studies are debating its benefits. Moreover, the introduction of immunotherapy in the management of the disease has raised new questions, and there is a lack of data on PCI and immunotherapy. We report a single-center retrospective study evaluating the impact of omitting PCI from real-life treatment, including immunotherapy, of patients with ES-SCLC. Methods: We identified patients followed at APHM between January 2014 and January 2021 for ES-SCLC without BM with an indication for PCI. The main assessment criteria considered in this study were overall survival (OS) and brain metastasis-free survival (BMFS) between patients who received PCI and those who did not. Results: 56 patients were included, 25 receiving PCI and 31 without PCI. The median follow-up was 16 months. Eighteen patients received immunotherapy, mostly in the group without PCI (p = 0.024). The median OS and BMFS were, respectively, 11.7 and 13.4 months in patients with PCI, and 20.3 and 10.7 months in patients without PCI, without any significant statistical difference (p = 0.412, p = 0.336). The prognostic factors highlighted in multivariate analysis were initial performance status (PS) < 2 for OS (HR = 2.74 (IC95% [1.23; 6.13])) and monocyte lymphocyte ratio (MLR) < 0.12 for BMFS (HR = 1.21 (IC95% [1.01; 1.45])). A recursive partitioning analysis (RPA) found PS, immunotherapy, and age to be influential factors for OS but not PCI. Conclusions: The clinical results of our study showed no benefit of PCI in terms of OS and BMFS for patients with ES-SCLC. This can be explained by the lack of benefit of PCI or by the introduction of immunotherapy. Full article
(This article belongs to the Special Issue Educating Recent Updates on Metastatic Non-small Cell Lung Cancer)
►▼ Show Figures

Figure 1

13 pages, 1391 KiB  
Article
Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials
by Tzu-Rong Peng, Ta-Wei Wu, Tai-Yung Yi and An-Jan Wu
Cancers 2024, 16(21), 3676; https://doi.org/10.3390/cancers16213676 - 30 Oct 2024
Cited by 3 | Viewed by 2521
Abstract
Background: The KRAS G12C mutation, prevalent in various malignancies, including non-small cell lung cancer (NSCLC), represents a unique therapeutic target. Adagrasib and sotorasib, two FDA-approved agents specifically targeting this mutation, have shown promise in clinical trials. This study aims to compare their [...] Read more.
Background: The KRAS G12C mutation, prevalent in various malignancies, including non-small cell lung cancer (NSCLC), represents a unique therapeutic target. Adagrasib and sotorasib, two FDA-approved agents specifically targeting this mutation, have shown promise in clinical trials. This study aims to compare their efficacy in treating KRAS G12C-mutated NSCLC, drawing insights from pivotal clinical trials. Methods: We analyzed data from three key clinical trials: KRYSTAL-1, CodeBreak100, and CodeBreak200. Our methodology involved reconstructing individual patient data from published Kaplan–Meier curves using the IPDfromKM tool (Version 0.1.10). The primary endpoints were progression-free survival (PFS) and overall survival (OS), evaluated through hazard ratios (HRs) and the restricted mean survival time (RMST) method. Results: The HR for PFS favored adagrasib (HR: 0.90 [95% CI: 0.69, 1.19], p = 0.473), suggesting a non-significant trend toward better disease control compared to sotorasib. For OS, the HR was 0.99 [95% CI: 0.75, 1.33] (p = 0.969), indicating no significant difference between the two drugs. RMST analysis supported these findings, with adagrasib showing a consistently higher RMST in PFS at 6, 12, and 18 months. However, OS benefits converged over time, with adagrasib marginally surpassing sotorasib by the 18-month mark. Conclusions: This comprehensive analysis reveals that while adagrasib may offer a slight advantage in PFS, both drugs demonstrate comparable efficacy in OS for KRAS G12C-mutated NSCLC. The subtle differences observed, particularly in PFS, could inform clinical decision-making, emphasizing the need for personalized treatment strategies. Future research should focus on long-term effects and identifying patient subgroups that may benefit more from one drug over the other. Full article
(This article belongs to the Special Issue Educating Recent Updates on Metastatic Non-small Cell Lung Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop